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AIM OF THE STUDY
1. To  evaluate  the  biochemical,  radiological  and  ultrasonographic 
aspects of Chronic Kidney Disease at the time of diagnosis.
2. To study the prevalence of cardiac changes in patients with Chronic 
Kidney Disease(CKD) 
3. To  study  the  Left  Ventricular  function,  and  its  relationship  with 




In health, the volume and composition of body fluids vary within narrow 
limits and kidneys are largely responsible for maintaining this state. They 
also subserve a host of metabolic and endocrine functions.  The failure of 
renal function results ultimately in alterations of milieu interior, that affects 
every organ system in the body.
          Chronic Kidney Disease is a clinical syndrome due to persistent renal 
dysfunction leading to excretory, metabolic and synthetic failure culminating 
in accumulation  of  non protein nitrogenous substances  and presents  with 
varied clinical features.  As soon as the cause for CKD is established, further 
evaluation is used as needed to preserve or restore glomerular filtration rate. 
In particular, evaluation of cardiovascular risk factors is critical, because of 
high rate of cardiovascular complications in CKD.
          History and measurement of renal size are helpful in establishing the 
chronicity of disease1.  It is important to note that no specific blood or urine 
test  unequivocally  differentiates  acute  from  chronic  kidney  disease. 
Creatinine  concentration  in  finger  nail  can  establish  chronicity  but 
determination is not available in clinical practice2.  The most sensitive and 
specific test for establishing the chronicity of kidney disease is measurement 
of renal size.  Currently renal ultrasonography is the technique of choice. 
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The  finding  of  small  kidneys  (i.e.  small,  relative  to  body  size)  on  renal 
ultrasonography  is a reliable indicator of CKD.  Renal biopsy is the most 
definitive method of differentiating acute from chronic kidney disease.
          Easy fatigability, dyspnoea, pedal edema, syncope, angina are the 
usual cardiovascular symptoms that are frequently encountered in patients 
with  advanced  renal  failure.   Structural  and  functional  cardiovascular 
evaluation  is  done  using  X-Rays,  Electrocardiography,  and 
Echocardiography.
          Cardiovascular disease accounts for about 50% of all  deaths in 
patients with CKD. Left Ventricular dysfunction is estimated to be present in 
65% of such patients. All patients with mild to moderate Left Ventricular 




1. CKD  –  Historical  aspects 
2. Definition  &  Staging  of  CKD
3. Pathophysiology  of  Uremia  and  clinical  features
4. Cardiovascular  Manifestations  in  CKD
5. Electrocardiographic  changes  in  CKD
6. Echocardiography
 Before going for discussion about cardiac manifestations in CKD a short 
description about CKD will be useful.
CKD – Historical aspects
The term Uremia was coined by Piorry and L’Heretier in 1840, because they 
thought  that  the  clinical  manifestations  of  kidney  diseases  was  due  to 
retention of urea in the blood. This theory persisted up to twentieth century 
and the role of urea and other related toxins were particularly emphasized.
The modern era of uremic symptoms began in the first half of twentyfirst 
century with works of Richard Bright.  He  described  the  progression of 
symptoms in patients suffering from kidney diseases which later came to be 
called as Bright’s disease.
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Definition of CKD
CKD is defined as kidney damage with or  without decreased glomerular 
filtration  rate  (GFR),  manifested  as  either  pathologic  abnormalities,  or 
markers  of  kidney  damage  that  include  abnormalities  in  composition  of 
blood  or  urine,  abnormal  renal  imaging  findings  and  GFR  less  than 
60ml/min 1.73m2.  This broad definition includes patients with or without 
symptoms of kidney diseases. 
Staging of CKD
K/DOQI Guidelines
Stage                                 Description                           Estimated GFR
                                                                                             In ml / min
                               At increased risk                                > 90 
1. Kidney damaged with
                          Normal or increased GFR                  ≥ 90
2. Kidney damaged with mildly
                          Decreased GFR                                  60-89
3.                      Moderately decreased GFR                30-59
4.                      Severely decreased GFR                    15-29
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5.                      Kidney failure                                    < 15
                            Pathophysiology  of  Uremia
In  Chronic Renal  Failure  (CRF) compensatory  and adaptive mechanisms 
maintain  acceptable  health  until  the  GFR is  about  10-15ml/min  and  life 
sustaining renal excretory and homeostatic functions continue until the GFR 
is less than 5ml/min.   The favored explanation centers on “intact nephron 
hypothesis”  first  proposed  by  Bricker,  which  states  that  the  functioning 
nephrons  compensate  for  their  non-functioning  nephrons.   This  does  not 
come without the price and “trade off hypothesis” has to be considered along 
side  the  intact  nephron  hypothesis.   The  best  example  is  the  secondary 
hyperparathyroidism to maintain the normal phosphate level which in turn 
leads to metastatic calcification.
Although many of the manifestations of uremic syndrome are attributed to 
derangement  in  electrolyte  concentrations,  fluid  imbalance  and endocrine 
deficiencies, there are others that are explained by action of substances and 
metabolites  retained  because  of  excretory  failure.   Examples  include 
encephalopathy, platelet dysfunction, glucose intolerance, and anemia and 
leukocyte dysfunction.  The substances those are responsible for this uremic 
syndrome are called as Middle Molecules.
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Some of the Examples are:
1. Homocysteine – Atherogenic
2. Methyl guanidine – neurotoxin that causes peripheral neuropathy
3. Amino  guanidine  –  potent  inhibitor  of  Nitric  Oxide  that  leads  to 
hypertension
4.  β2 Micro globulin – amyloid
5. Drugs such as Morphine – accumulate and cause encephalopathy.
Cardiovascular Manifestations in CKD
Introduction
Cardiovascular disease is recognized as the predominant cause of death 
in  CKD.   Most  clinical  consequences  of  cardiac  disease  result  from 
cardiomyopathy  or  ischemic  heart  disease.   Cardiomyopathy  may 
manifest as an enlarged, dilated Left Ventricle, with systolic dysfunction 
or  hypertrophic  ventricle  with  diastolic  dysfunction,  with  or  without 
myocardial ischemia.  CKD causes accelerated atherosclerosis and also 
arteriosclerosis.   Ischemic  symptoms  result  from  Coronary  Artery 
Disease (CAD) or arteriosclerosis.  Arteriosclerosis contribute directly to 
ischemic  symptoms,  Left  Ventricular  hypertrophy  (LVH),  systolic 
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dysfunction  by  increasing  cardiac  workload.  CAD  predisposes  to 
diastolic dysfunction (DD) and systolic dysfunction.  
Most valvular lesions observed in patients with CKD are acquired and 
develop from dystrophic calcifications of valvular annulus and leaflets, 
particularly aortic  and mitral  valves4.   Such calcification  is  present  in 
55% of aortic valve and 39% of mitral valve5, 6.  Once considered benign, 
aortic  valve  sclerosis  is  associated  with  increased  cardiovascular 
mortality in general community7.   LVH is evident in 40% of the patients 
with  moderate  renal  insufficiency8 and  75%  of  those  commencing 
dialysis9.   Associated  risk  factors  including  Diabetes,  Hypertension, 
tobacco use and anemia predisposed to much more rapid development of 
symptomatic cardiomyopathy10.
Risk factors for cardiovascular involvement in CKD
1. Hypertension
It is prominent in all stages of CKD whatever the etiology.  It is a strong 
predictor  for  LVH,  cardiac  dilatation,  cardiac  failure,  ischemic  heart 
disease and worsening of atherosclerosis38.   There is a blunting of the 
nocturnal  dip  in  blood  pressure  in  uremia  which  puts  the  patients  at 
higher risk for vascular diseases.  Impairment of cardiac perfusion during 
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diastole,  particularly  in  the  presence  of  LVH  or  decreased  aortic 
compliance leads to ischemic myocardial damage.
2. Lipids
Renal dyslipidemia39, 40 is reflected in an abnormal apolipoprotein profile 
–  decreased  High Density  Lipoprotein  and increased  concentration  of 
Very  Low Density  Lipoprotein,  Intermediate  Density  Lipoprotein  and 
Low Density Lipoprotein.  A significantly decreased Apo A-II to Apo C-
III is  the hallmark of altered lipoprotein composition in renal  disease, 
thereby promoting atherosclerosis.
3. Diabetes 
It predicts deterioration in cardiovascular state, regardless of the presence 
of  cardiovascular  disease  at  baseline41.   Diabetes  leads  to 
microalbuminuria, a  marker of early diabetic nephropathy, that  signifies 
vascular endothelial dysfunction.  Echocardiographic  LVH  is probably a 
more  frequent  finding  in  hypertensive  diabetic  patients  than  in 
hypertensive non-diabetic patients.
4. Hypoalbuminemia
It  is  emerging  as  a  powerful  risk  factor  for  cardiovascular  mortality 
besides all cause mortality, especially in dialysis patients.  Malnutrition 
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also can lead to low folate, B12 levels and low arginine in turn leading 
further  to  hyperhomocysteinemia  and impaired  Nitric  oxide  synthesis. 
Low  level  of  antithrombotic  proteins  leads  to  hypercoagulability54. 
Inflammation also causes decrease in albumin synthesis and increase in 
albumin fractional catabolic rate. This inflammatory response alters the 
endothelium and plasma protein composition in ways favoring vascular 
injury.
5.Malnutrition-Inflammation-Atherosclerosis Syndrome(MIA)
Uremia is a state of chronic inflammation.  Reduced renal clearance of 
cytokines,  accumulation  of  Advanced  Glycation  End  Products  (AGE) 
and unrecognized persistent infections are some of the causes.  Levels of 
pro inflammatory cytokines such as IL1, IL6, TNF α are increased 8 to 10 
fold.  IL6 is  an  important  pro  atherogenic  cytokine  that  alter  insulin 
sensitivity and endothelial function.  It is a strong stimulant of adhesion 
molecules (VCAM, ICAM) which mediates attachment and migration of 
leucocytes across the endothelial surface.   The sustained inflammatory 
reaction promotes endothelial dysfunction, oxidative stress, complement 
activation and leads to increased cardiovascular mortality.
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6. Hyperhomocysteinemia
It  is  a  strong  predictor  of  cardiovascular  disease  in  the  general 
population55 ,56 and appears to be associated with further risk in patients 
with CKD57.   In CRF,  homocysteine  levels  range from moderate  (16-
30µmol/L) to intermediate (30-100µmol/L).  It enhances vascular smooth 
muscle  proliferation,  increases  platelet  aggregation  and  act  on  the 
coagulation cascade and fibrinolysis  directly  inducing a prothrombotic 
environment or by acting in a synergistic manner with other risk factors. 
It activates coagulation factors V, X, XII along with decreased activation 
of protein C and cell surface  thrombomodulin  and  modulation  of tissue 
plasminogen  activator  binding  to  its  endothelial receptor -annexin II.
The  proposed  mechanisms  of   homocysteine  toxicity  are  oxidative 
stress  through  production  of  reactive  oxygen  species, binding  to 
nitric  oxide,  production of  homocysteinylated /acylated  proteins  and 
accumulation of  its  precursor  S-Adenosyl homocysteine-a  potent 
inhibitor  of transmethylation  reactions. 
7. Role of ADMA(Asymmetric Dimethyl Arginine)
ADMA  is  a  new  emerging  cardiovascular  risk  factor  considered  in 
uremic  patients.   It  is  a  competitive  Nitric  Oxide  synthetase  inhibitor 
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leading to decreased Nitrous Oxide availability. ADMA is degraded by 
dimethyl  arginine  dimethyl  aminohydrolase-an  enzyme  rich  in  renal 
tissue.   With  advancing  renal  failure  and  loss  of  renal  mass  ADMA 
accumulates.   In  ESRD,  it  is  the  second  strongest  predictor  of 
cardiovascular mortality, after age, among the traditional risk factors.  
8. Angiotensin II
The Renin Angiotensin system is activated in most of the renal diseases 
especially  in diabetics  and hypertensive.   Emerging evidences  suggest 
that  the  resultant  increased  Angiotensin  II  is  not  only  a  vasoactive 
peptide but also a true cytokine that regulates cell growth, inflammation 
and fibrosis.  Angiotensin-II increases TNF α production which regulates 
various cell processes including cell proliferation and production of other 
cytokines  and  adhesion  molecules.   It  also  up  regulates  other  pro-
inflammatory mediators-IL-6, NF-k β and thus plays an active role on the 
inflammatory response in renal diseases.  It stimulates superoxide lipid 
per oxidation and inactivation of NO producing oxidative stress. 
 Atherosclerosis is promoted by Angiotensin-II, by production of lipid 
into the foam cells of the vessel wall, and by Endothelial Dysfunction.  It 
induces  endothelial  cell  apoptosis,  which  has  dramatic  effects  on  the 
platelet  cell  binding  and  on  the  inflammatory  process.   The  various 
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metalloproteinases  induced  by  Ang-II,MMP-1,  MMP-9,  etc.  lead  to 
proliferation, migration and hypertrophy of vascular smooth muscles and 
promote matrix expansion and fibrosis.
9. Calcium, Phosphorus and Parathormone  (PTH)  in CKD
Progressive  nephron  loss  is  associated  with  phosphate  retention  and 
hypocalcemia.   This  triggers  increased  parathormone  activity.   The 
secondary  hyperparathyroidism  along  with  hyperphosphatemia  and 
increased calcium phosphate ion product are identified as independent 
cardiovascular  risk  factors.   Decreased  cardiac  contraction,  LVH and 
valvular  calcification  culminate.   An increase  in  calcium-phosphorous 
product  >  60  mg2/dl2 promotes  metastatic  calcification.   Vascular 
calcification begins 10-20 years earlier than in the general population.  
There  is  substantial  experimental  and  clinical  evidence  that  the 
hyperparathyroid  state  and  altered  vitamin  D  status  found  in  uremia 
contribute  to  cardiomyopathy,  LV  hypertrophy,  LV  fibrosis, 
atherosclerosis,  myocardial  ischemia,  and  vascular  and  cardiac 
calcification61.
A  viable  hypothesis  is  that  the  disturbed  divalent  ion  metabolism 
promotes  vascular  calcification,  which  produces  non-compliant  major 
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vessels.  This in turn predisposes to LV hypertrophy, cardiac disease, and 
subsequent death.
10. Oxidative Stress
Oxidative stress  is  said to  occur  when there is  an imbalance  between 
formation  of  reactive  oxygen  species  (ROS)  and  antioxidant  defense 
mechanisms.   ROS  (e.g.  hydrogen  peroxide,  free  radicals  such  as 
superoxide, hydroxyl radical) are continuously formed in vivo and play 
an important role in host defense against tumor cells and pathogens.  A 
number  of  enzymatic  and  non  enzymatic  defense  mechanisms  have 
evolved  to  “detoxify”  ROS.   The  predominant  non  enzymatic  agents 
include vitamin E, vitamin C, selenium, and zinc.  Superoxide dismutase 
and glutathione peroxidase are the main antioxidants.  It is thought that 
oxidative stress  is  important  in  the  formation of  atheroma,  because  it 
generates  lipid  peroxidation  products  that  are  consistently  found  in 
atheromatous streaks and sclerotic lesions59, 60.  
Compelling  evidence  indicates  that  oxidative  stress  is  an  important 
trigger in the complex chain of events leading to atherosclerosis in CKD. 
Enhanced  oxidative  stress  may  be  identified  by  an  increase  in  the 
products  of  lipid  per  oxidation  (e.g.  malondialdehyde),  a  decrease  in 
substances  that  enhance  oxidative  resistance  (e.g.  plasmalogen),  or  a 
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decrease in reducing substances (e.g. glutathione).  There is evidence for 
all of these in CKD.
11. Increased extra cellular Volume
At all  stages  of  CKD, sodium and water  overload may  cause  plasma 
volume expansion,  LV dilatation  and LV hypertrophy.   However,  the 
main group affected is the dialysis patients.   LV hypertrophy is more 
severe  in  long-term  peritoneal  dialysis  patients  than  in  hemodialysis 
patients46.  This finding is associated with evidence of more pronounced 
volume expansion, hypertension, and hypoalbuminemia. 
12. Arteriovenous Fistulas
Blood  flow in  arteriovenous   fistulas  and   grafts   predisposes  to  LV 
volume  overload.
13. Arteriosclerosis
Increased  pulse  pressure  and  Systolic   Blood   Pressure  are  closely 
correlated with LV hypertrophy47, 48.  Raised pulse pressure49, 51, increased 
carotid wall thickness52 and elevated pulse wave velocity53 have all been 
associated with an increased mortality.  For any given systolic pressure, 
pulse pressure of more than 50 mm Hg correlates with increased risk of 
death.
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14.  Anemia-A Crucial Factor in the Vicious Cycle of Cardio renal 
Syndrome
The kidney being the main source of erythropoietin, anemia is apparently 
an integral part of advancing renal failure. 
Low hemoglobin results in low oxygen delivery, reduced blood viscosity, 
reduced peripheral  resistance leading to increased sympathetic  activity 
and venous return.  The resultant high cardiac output and high arterial 
volume  lead  to  adaptive  Left  Ventricular  Hypertrophy  and  arterial 
hypertrophy and defective cardiac remodeling. 
Current guidelines define anemia as hemoglobin concentration less than 
11 gm / dl in pre menopausal women and less than 12 gm / dl in males 
and post menopausal females. 
In heart failure there is reduced blood pressure,  increased sympathetic 
activity,  and decreased renal  blood flow.   It  induces  cytokines  which 
depress the bone marrow.   The erythropoietin  levels  which should be 
1000 times normal barely go up because of the inhibitory effect of TNF 
and renal disease. 
The  cytokines  Tumor  Necrosis  Factor  and  interleukin-6  can  decrease 
erythropoietin  production  in  the  kidney,  increase  erythropoietin 
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resistance in the bone marrow and decrease the release of iron from the 
reticuloendothelial  system. TNF also interferes with the iron absorption 
in the gut.
Proteinuria  itself causes loss of erythropoietin, iron, and  transferrin, one 
reason  why  patients  with  nephrotic  syndrome  become  anemic.   In 
diabetics, glycosylation of the interstitial cells that produce erythropoietin 
lead to inappropriately low hemoglobin, the  condition  that   is  referred 
to  as   diabetic   myocardiopathy   in  many  cases,  may  simply  be  the 
anemia  not  treated  adequately. 
It  is  an  independent  risk  factor  for  the  development  of 
electrocardiographically diagnosed LV hypertrophy43 and of symptomatic 
heart  failure38.   In  moderate  to  severe  CKD before  dialysis  (GFR<50 
ml/min), anemia is associated with LV growth.  In dialysis patients, it is 
associated  with  progressive  LV dilatation  and  hypertrophy44 and  with 
development of de novo heart failure45.
For every 1gm/dl drop in mean hemoglobin, the risk of cardiac failure 
(de novo) increases by 25%, echocardiographically demonstrable LVH 
by 42% and risk of death increases by 14%.
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Clinical Manifestations of cardiovascular system in CKD
1. LVH 
Left  Ventricular  Hypertrophy  is  due  to  excessive  pressure  &  volume 
loads. The principal factors comprising pressure & volume overload in 
patients with CKD are collectively known as hemodynamic risk factors.
Pressure overload results from sustained increases in LV after load  that 
includes  predominantly  Hypertension,  and  Arteriosclerosis. 
Volume overload embraces increased extra cellular volume, anemia and 
arteriovenous fistula.
 Left  Ventricular  Hypertrophy  can  be  concentric  or  eccentric11 
(asymmetrical).   Concentric  hypertrophy  is  considered  an  adaptive 
mechanism in response to chronic LV pressure over load.  It is associated 
with increased thickness of both intra ventricular septum and LV free (or 
posterior) wall. The overall volume of ventricle remains normal, so that 
relative to the LV End diastolic diameter, wall thickness is increased. 
 Eccentric hypertrophy is a mechanism of adaptation to chronic volume 
over load in which LV end diastolic pressure tends to normalize at the 
expense of increased end diastolic volume.
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Asymmetric hypertrophy is a variant of concentric hypertrophy whereby 
the  septal  wall  is  disproportionately  thickened  in  relation  to  the  LV 
posterior  wall.  This  can  result  from an  increase  in  after  load,  which 
exposes the septum to greater stress  than free wall, or from stimulation 
of sympathetic  nervous  system.
2. Cardiac Failure
Functional Abnormalities
Assessment of LV functional abnormalities in patients with CKD is often 
difficult. Absence of symptoms does not imply intact functional reserve, 
regardless of the stage of the disease.
Diastolic dysfunction
CKD patients  often have some impairment  in LV diastolic  function12. 
The  abnormal  ventricular  filling  in  uremia  results  from increased  LV 
stiffness caused by intramyocardial fibrosis and associated with delayed 
relaxation.  By virtue of  an increase in LV stiffness,  small  changes in 
volume  results  in  large  changes  in  LV  pressure,  predisposing  to 
symptomatic pulmonary edema.
The reverse  is  also true:  volume depletion results  in  large fall  in  LV 
pressure with  symptomatic hypotension  and  hemodynamic  instability.
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This is often the presenting feature of diastolic dysfunction.
Systolic dysfunction
 Resting systolic function is usually normal or increased in patients with 
advanced renal disease in the absence of antecedent cardiac disease13-15. 
Approximately  15% of  patients  have  systolic  dysfunction  by the  time 
they start  dialysis.  Diminished  myocardial  contractility  may  also  be  a 
result of overload cardiomyopathy, in which the myocardium relies on 
Starling forces to maintain a normal cardiac output. 
This  manifestation  of  cardiomyopathy  has  a  substantially  worse 
prognosis  than that  for  either  concentric hypertrophy or LV dilatation 
with normal systolic function.
3. Ischemic  Heart  Disease
In  humans,  basal  myocardial  perfusion  tends  to  remain  constant 
regardless of the severity of coronary  artery  stenosis.
During  conditions  requiring  increased  flow,  a  progressive  relative 
decrease  in  perfusion  occurs  after  the  degree  of  stenosis  is  40%  or 
greater, and perfusion cannot increase above basal conditions when the 
stenosis  is  80% or greater.
It appears  that  uremic  milieu  favor  vascular  wall  damage.
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Coronary  Artery  Disease,  characterized  by  critical  stenosis  of  major 
coronary arteries is highly prevalent in the CKD population.
Atheromatous ischemic heart disease in CKD is due to dyslipidemias, 
increased  prothrombotic  factors16,  increased  oxidative  stress  that 
enhances  atherogenesis17,  hyperhomocysteinemia18,  19,  disturbance  of 
glucose metabolism20and cytokine activation.
Two  factors  have  been  suggested  to  play  an  important  role  in  the 
formation of atheroma: Inflammation & Vascular calcification.
Evidence has shown that inflammation and C Reactive Protein (CRP) in 
general, contributes directly to atherosclerosis. CRP has been shown to 
bind to damaged cells,  promoting activation of complement  system. It 
displays  calcium  dependent  binding  and  aggregation  of  Low  Density 
Lipoproteins  and  Very  Low  Density  Lipoproteins.  It  is  a  potent 
stimulator of tissue factor by  monocytes.
Coronary atherosclerotic plaque morphology in patients with CKD was 
distinguished  by  abundant  calcium deposition  and  such  deposits  may 




They  are  due  to  disturbances  in  serum levels  of  electrolytes  that  can 
affect cardiac conduction including Potassium, Calcium, Magnesium21, 22. 
Old  age,  preexisting  heart  disease,  LVH  are  associated  with  high 
prevalence of cardiac arrhythmias23-25.
4. Valvular  Heart  Disease
Prevalence  of  aortic  valve  calcification  in  dialysis  patients  is  55%26,  4 
similar to that in elderly general population, although it occurs 10 to 20 
years earlier27-29.
Aortic  valve  stenosis  in  CKD  evolves  from  valve  sclerosis7 .It  may 
sometimes evolve rapidly to hemodynamically significant stenosis, with 
worsening of LVH and rapidly evolving symptomatology.  
Age, increased phosphate level, increased Calcium Phosphorous product 
are the most important risk factor for development of aortic stenosis26, 30. 
Mitral valve annulus calcification is present in 15% of the patients31. Risk 
factors are involvement of posterior cusp, Left atrial dilatation, duration 
of pre-dialysis systolic hypertension32.
Factors  associated  with  decreased  survival  include  severity  of 
calcification, mitral regurgitation and decreased LV function.
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5. Arteriosclerosis
It  is  defined  as  diffuse,  non  occlusive  medial  and  intimal  wall 
hypertrophy.  It  has  been  correlated  with  short  stature,  male  gender, 
smoking, blood pressure, volume overload, humoral imbalance and age. 
The  process  of  arteriosclerosis  is  accelerated  in  CKD  patients. 
Arteriosclerosis  leads  to  increased  peripheral  vascular  resistance. 
Increased peripheral resistance is characterized principally by increased 
diastolic pressure and mean blood pressure. Whereas increased arterial 
stiffness is indicated by increased systolic blood pressure and widened 
pulse  pressure.  Increased  systolic  blood  pressure  and  widened  pulse 
pressure are closely correlated with LV hypertrophy.
6. Hypertension
It  is  due  to  increased  extra  cellular  volume  through  salt  and  water 
retention, enhanced sympathetic activity, activation of Renin Angiotensin 
Aldosterone  system  and  endothelial  dysfunction33-35.Additional  factors 
include renal vasculopathy36, hyperparathyroidism37.
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Electrocardiographic Changes in CKD62
The electrocardiographic changes in CKD are due to 
1.  LVH  2.Hypokalemia  3.  Hyperkalemia  4.  Hypocalcemia  5. 
Hypercalcemia  6.  Pericarditis  7.  Ischemic  Changes  8.  Pericardial 
Effusion 
1. LVH 
LV dilatation produces incomplete LBBB.
Romhilt Estes Scoring System For LVH
i)  R or S in limb lead I  ≥ 20 mm 
Or S in lead V1 or V2
Or R in lead V5 orV6 ≥ 30 mm      3 points
ii) LV Strain
ST segment and T wave in opposite direction to QRS complex
Without Digitalis                                                   3 points
With digitalis                                                                            1 point.
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iii ) Left  Atrial  Enlargement 
Terminal negativity of P wave in lead V1 ≥ 0.10 mV in depth & 
≥ 0.04 s in duration                                                                3 points
iv)  Left Axis deviation ≥ - 30degrees                       2 points
v)   QRS duration ≥ 0.09s                                                      1 point
vi)  Intrinsicoid deflection in lead V5 ≥ 0.05s                        1 point
                    Total                                                                 15 points
           LVH   -  5 points  
Probable LVH - 4 points
2. Hypokalemia
a) Flattening or inversion of T wave 
b) Increased prominence of U wave
c) Slight depression of ST segment 
d) Increased amplitude and width of  P wave
e) Prolongation of  PR interval 
f) Premature beats and  sustained  tachyarrhythmias
g) Prolongation  of  QTc  interval
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3. Hyperkalemia
a) Increased  amplitude and peaking of  T wave
b) Prolongation of  PR interval
c) Prolongation of QRS interval
d) Flattening of P wave
e) Disappearing ST segment 
4. Calcium Derangement
a) Hypocalcemia - prolonged  QTc  interval 
b) Hypercalcemia  - shortened  QTc  interval
QTc =  QT/√R-R
5. Hypermagnesemia 
It simulates Hyperkalemia.
a) Widened  QRS complex
b) Prolongation of PR segment.
6. Pericarditis
It is associated with 3 basic ECG abnormalities
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Effect of acute pericardial injury
Acute pericarditis injures the epicardial surface of heart.  This results in a 
shell of injured tissue, surrounding the heart, the brunt of which affects the 
apical  segments.   This  is  reflected  by  ST  deviation  towards  the  injured 
surfaces.
Effects on epicardial Ischemia
It is reflected by T wave inversion from the ischemic region.
i) Acute pericarditis
T wave change
During the very early phase of acute pericarditis, T wave usually becomes 
slightly taller, peaked and symmetrical.  This may be the earliest sign.
ST segment changes
The epicardial  injury  is  reflected  as  raised  ST segment  in  leads  oriented 
towards affected surface.  Since there is no myocardial ischemia, T waves 
remain upright.   The concavity in ST segment  is facing upwards (saddle 
shaped).
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Sub acute phase   
ST  segment  tends  to  become  convex  upwards.  The  T  wave  loses  its 
amplitude and becomes isoelectric. It eventually becomes inverted heralding 
the onset of chronic stage. ST also moves towards the base line.
ii) Chronic Pericarditis
T wave 
Epicardial injury can progress to epicardial ischemia due to an associated 
myocarditis  of  epicardial  layer.   This  results  in  widespread  T  wave 
inversion. 
Low voltage complexes
This is due to short circuiting of electrical impulses by surrounding effusion.
Electrical Alternans
This  manifest  when there is substantial effusion, frequently seen in mid pre 
-cordial leads.
7. Pericardial Effusion 
a) Low voltage complexes 
b) Widespread  ST segment elevation
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c) It  causes  short  circuiting  of  electrical  impulse.   This  results  in 
diminished  magnitude  of  P,  QRS  and  T  wave  as  well  as  Total 
Electrical Alternans.
8. Ischemic Changes
a) Symmetric  T wave inversion, b) ST segment flattening 
c) Upwards sloping of  ST segment depression, 
d) Plane ST depression
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Echocardiography
The  term echocardiography  refers  to  evaluation  of  cardiac  structure  and 
function with images and recordings produced by ultrasound.  In the past 
three decades, it has rapidly become a fundamental component of cardiac 
evaluation.  The development of echocardiography is credited to Elder and 
Hertz in 1954.  
Types 
1. M – mode  Echo 2. Two  dimensional  Echo 3. Doppler Echo (continuous 
wave Doppler, pulsed wave Doppler, spectral Doppler) 4.Transesophageal 
Echo 5.Intravascular Ultrasonography 6. Fetal  Echo 7. Three dimensional 
Echo
Advantages
1. M – mode Echo (M – motion)
Temporal resolution will be good. It can detect minimal pericardial effusion. 
It is used to obtain cardiac measurements.
2. 2-D Echo
Spatial  resolution  will  be  good.   Anatomical  details  of  chambers,  great 
vessels, valves can be studied in a better way.
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3. Doppler Echo
It is used to detect  stenosis or regurgitation  and any shunt across inter atrial 
septum, inter ventricular septum, and for assessing diastolic function.  
 Continuous wave Doppler is used for quantification of valvular  stenosis or 
regurgitation.
4. Trans esophageal Echo
It is helpful in assessing prosthetic valves, vegetations, aortic disease and 
intra cardiac masses.  
It is used to monitor cardiac LV function throughout surgical procedure and 
into the post operative state.
Two Dimensional Echo
Two dimensional scanners utilize B-mode scan lines that are independently 
transmitted and received and are directed through a wedge shaped sector of 
cardiac anatomy by means of mechanical or electrical beam steering.
Standard 2D Echo cardio graphic transducer positions
Parasternal Position
Long axis
           LV long axis
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           RV long axis
           RV outflow
Short axis
Through the plane of 
           The cardiac base
           The mitral valve
           The chordae tendinae
           The papillary muscles








Short axis through plane of 
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           Mitral  valve
           Papillary muscle 
           Cardiac base
Suprasternal Position
Long axis (through ascending and descending aorta)
Short axis
Left  parasternal  position in long axis view provide excellent images of  LV, 
Aorta, LA, mitral and aortic valves.
RV long axis view visualizes RA, RV and Tricuspid Valve.
In RV outflow view, Pulmonary Vein and Pulmonary Artery are seen.
The four chamber views are obtained from apical and sub costal positions.
Echocardiogram – Normal values
M – Mode measurements 
LV function
i) LV end diastolic dimension (LVD)                            3.7 - 5.6 cm
ii) LV end systolic dimension (LVS)                              2.2 - 4.0 cm
iii) Inter ventricular septal thickness                               0.6 - 1.2 cm
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iv) LV  posterior wall thickness                                       0.5 - 1.0 cm
v) Fractional Shortening                24 - 42%
vi) Ejection  Fraction        55-60%
Mitral valve
i) MV  EF slope                                                      70 - 140 mm/sec
ii) MV DE amplitude                                                1.5 - 2.0 cm
iii) EPSS          0.9 cm
Aorta
i) Aortic  Root diameter                  2.0 - 3.7 cm
ii) Aortic valve opening                            1.5 - 2.6 cm
Left Atrium
LA dimension          0.7 - 2.6 cm
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Materials and Methods
The study was conducted in patients  with CKD admitted in GRH, KMC 
during the period Jan – June 2007.
 The following criteria were used in the selection of cases.
1. Patients with GFR of 30-59 ml/min
And/or
2. Patients with bilateral contracted kidneys on abdominal ultra sound with 
poor cortical medullary differentiation.
3. Patients with established CKD irrespective of etiology.
4.  Patients  with  known Valvular  Heart  disease,  Coronary  artery  disease, 
Systemic Hypertension on regular treatment & patients with poor pulmonary 
function were excluded.
In all patients, detailed history of illness was taken with special reference to 
cardiovascular symptoms and subjected to a complete clinical examination.
Blood  biochemical  investigations,  ECG,  Abdominal  ultrasonography, 
complete hemogram were performed.
Echocardiography was done in all patients by a single echocardiographist to 
minimize observer variation.
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GFR was calculated using Cockgraft-Gault Formula
In males 
GFR = 1.2 × (140-age in years) × weight in kg / creatinine concentration in 
µ mol/L
In females the multiplying factor is 0.85 instead of 1.2.
Systolic function
In  our  study,  systolic  function  is  assessed  mainly  based  upon  M-mode 
measurements of LV function.
The ejection fraction is measured.
Normal range                                     55-80%
Mild systolic dysfunction                  45-50%
Moderate systolic dysfunction          35-45%
Severe systolic dysfunction              <35 %
Diastolic function (Pulsed wave Doppler study)
Diastolic  function  is  assessed  by  measuring  mitral  inflow,  E/A 
measurements.
1. E/V-in m/s. it indicates initial mitral flow which causes ventricular filling 
following the opening of mitral valve.
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2. A/V-in m/s. it indicates ventricular filling due to atrial systole.
3. E/A-is usually >1. E/A<1   indicates diastolic dysfunction.
Type I – Relaxation abnormality 
Type II – Pseudo normalization 
Type III – Restrictive abnormality
Regurgitation (color flow Doppler study)
Mitral regurgitation / tricuspid regurgitation
When regurgitation jet extends
Up to 1/3 of atrium : mild
1/2 of atrium          : moderate
Posterior wall of atrium : severe
Aortic regurgitation
Jet height / LVOT height
Mild : ratio less than 20
Moderate : 20-40
Severe : more than 40
Pericardial effusion
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Uremia produces chronic pericardial effusions. The pericardial fluid is 
hemorrhagic. Echocardiography is the procedure of choice for the diagnosis 
of pericardial effusion. The diagnostic feature on M mode echo is the 
persistence of an echo free space between parietal and visceral pericardium 
throughout the cardiac cycle. 2 D Echo has superior spatial orientation and 
allows delineation of size and distribution of pericardial effusion.
They are described as small, moderate and large based on the size of echo 
free space between the parietal  and   visceral pericardium on 2 D Echo.
Small         : < 5 mm echo free space
Moderate   : 5 – 10 mm
Large          : > 10 mm
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In our study the average duration for cardiac disease to manifest in chronic 
kidney disease is 13-24 months.
Etiology                                                                             No. of Cases
i)     Chronic Glomerulonephritis  7
ii)    Hypertension                                                  3
iii)   Obstructive nephropathy                    4
iv)    Diabetic nephropathy                18
v)     Chronic interstitial nephritis                         6
vi)    Autosomal dominant polycystic kidney ds           2
The commonest etiology in our study group is Diabetes Mellitus.
In this study, 38 patients have hemoglobin below 12gm% of which 10 















































Concentric  LVH  is  the  most  common  echocardiographically  detected 




































Type I – Diastolic dysfunction is present in about 50% of the cases.
LV Contraction
Global  LV  hypokinesia is present in two cases.
Pericardial Effusion
Pericardial effusion is present in 20% of cases.
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DISCUSSION
Chronic renal failure is a constellation of signs and symptoms called uremia. 
It can present with features of involvement of any organ in the body.  The 
present study is about cardiac involvement in CKD.
• Electrocardiogram showed evidence of LVH with or without   strain 
pattern in 62.5% of cases.
• Low voltage complexes in 15% of cases.  
• Occasional ventricular premature complexes in 22.5% of cases.
• Non-specific ST – T changes in 30% of cases.
• Electrocardiogram  will  reveal  the  presence  of  LVH  and  previous 
ischemic events.
• It is a sensitive index of cardiac effects of  hyperkalemia.  
• More accurate assessment of LV function and hypertrophy requires 
echocardiography.  
• Regarding  cardiac  arrhythmias,  their  episodic  nature  makes 
identification and characterization difficult.
• Ideally 24 hours Holter monitoring, serial 12 lead ECG are necessary 
to detect ECG changes and cardiac arrhythmias in CKD patients.
49
• Gleason et al and Kimura et al23-25 concluded that arrhythmias are due 
to  acid  base  and  electrolyte  disturbances  and  underlying  ischemic 
heart disease.
• Non  sustained  supraventricular  tachyarrhythmias  are  common 
followed  by  ventricular  premature  complexes  and  ventricular 
tachycardia.
Echo revealed cardiac abnormalities in all cases.
Chamber dilatation
• 22.5% of Patients showed dilated LVH.
• 47.5% of Patients showed concentric LVH.
• In our study patients who have had long standing H/O Hypertension, 
show concentric LVH.
• The  only  major  determinant  of  LVH  in  our  study  was  the  blood 
pressure burden.  
• It correlates with the Harnett et al62 study on impact of hypertension 
on cardiomyopathy, morbidity, mortality in ESRD. 
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• The concentric LVH includes Intra ventricular septal thickness in End 
Diastole.  Anemia  is  an  important  determinant  of  End  Diastolic 
Diameter.  
• In our study  the  average Hemoglobin level was relatively 6-7gm%.63-
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• LA enlargement was not a frequent finding in our study.  It is thought 
to be due to diastolic dysfunction due to LVH.
Valves
• Aortosclerosis and Posterior Mitral Annulus Calcification is found in 
35% of patients in our study group.  
• Age,  duration  and  hyperparathyroidism  have  been  cited  as  prime 
determinants of  valvular calcification26, 27.  
• Myocardial fibrosis and cardiac calcification have been reported due 
to  metastatic calcification.
LV Function
• Systolic dysfunction - 27.5% of cases
• Diastolic dysfunction - 50% of cases
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• According to Kramer et al12 factors contributing to development  of 
CCF in patient with CKD are 
1.  Volume  over  load  2.  Valvular  heart  disease   3.  Negative 
inotropic  effects  of  Calcium 4.  Cardiac  arrhythmias  5.  Pressure 
overload  6. Myocardial damage  7. Anemia.
• In our study, patients with moderate LV dysfunction showed features 
of volume overload, anemia and long standing history.
• All  our  patients  revealed type I  relaxation  abnormality  of  diastolic 
dysfunction.
LV Contraction
• Global LV  Hypokinesia  reflects Dilated Cardiomyopathy.
Pericardial Effusion
• 20% of cases have pericardial effusion. 
• Hemorrhagic pericardial effusion is a well recognized complication of 
uremia.  
• In fact it can cause pericardial tamponade which is a life threatening 
emergency.  Pericardial disease is an urgent indication for dialysis69. 
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CONCLUSION
1.  41-50 year males were the most common affected people in our study 
group.
2. All patients were anemic.
3. The most common etiology was Diabetes.
4. LVH was the most common ECG finding noted.
5. Echo detection of cardiac changes was present in all patients.
6.  Echocardiography  is  an  invaluable  tool  in  detecting  early  cardiac 
abnormalities in CKD.  Hence Echo should be an integral part of assessment 
for renal transplant.
7.  Cardiac  changes  were  more  frequent  in  those  who were  in  advanced 
stages  of  chronic  renal  failure  reflecting a  positive correlation of  cardiac 
changes with the severity of chronic renal failure.
8. Concentric LVH was the most common echocardiographically detected 
abnormality.
Diastolic  dysfunction was present in 50% of cases and systolic dysfunction 
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Hypertension   Calculi UTI
Diabetes   AGE                                  Sore throat
Tuberculosis          Transfusion                          Scabies
Drugs      Proteinuria 
Jaundice                              Hematuria            
Personal History    
Smoking          Analgesics
Alcohol                 Indigenous medicines
Obstetric History
No. of Pregnancies / Abortion
Hypertension / Edema / Proteinuria
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Diabetes, Hypertension, Tuberculosis, Hematuria




Height                              Pulse                            Anemia                        Skin 
Weight                             BP                                Jaundice                      Nails
Build                               Temperature                 Edema                         Teeth
Face                                                                      Lymph node                Eyes
CVS
JVP                                   Heart sounds
Precordium                       Murmur
Apex beat                          Pericardial rub
RS
Trachea                             Breath sounds 
Chest movements             Adventitious sounds
Percussion 
Abdomen
Appearance                        Liver                            Kidney
Free fluid                           Spleen                          Bruit                             
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CNS              
Higher functions                 cranial nerves                        Spinomotor system
Sensory system                   Fundus   
Miscellaneous  
Bones / joints                      Genitalia
P / R                                     P / V
Lab Data
Urine              CBC                    Blood Bio-chemistry
Albumin              Hb             Urea                        HCO3
Sugar                   Tc           Creatinine                   Na
Deposits              Dc           Protein                         K
Pr / Cr                 PCV         A / G                          Ca,P
X – Ray
1. CXR     2. KUB – Abdomen  
USG
Kidney size                        Cortical  medullary differentiation 
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ECG
Rate                               Rhythm                        PR interval                    Axis 
ST - T changes              U waves                       Chamber hypertrophy
Echocardiography
LVd                                LVs                             EF 
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